Cargando…

Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells

Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα) cellular lifetime/accumulation. They are antagon...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosfield, David J, Weber, Sandra, Li, Nan-Sheng, Sauvage, Madline, Joiner, Carstyn F, Hancock, Govinda R, Sullivan, Emily A, Ndukwe, Estelle, Han, Ross, Cush, Sydney, Lainé, Muriel, Mader, Sylvie C, Greene, Geoffrey L, Fanning, Sean W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177151/
https://www.ncbi.nlm.nih.gov/pubmed/35575456
http://dx.doi.org/10.7554/eLife.72512
_version_ 1784722830166851584
author Hosfield, David J
Weber, Sandra
Li, Nan-Sheng
Sauvage, Madline
Joiner, Carstyn F
Hancock, Govinda R
Sullivan, Emily A
Ndukwe, Estelle
Han, Ross
Cush, Sydney
Lainé, Muriel
Mader, Sylvie C
Greene, Geoffrey L
Fanning, Sean W
author_facet Hosfield, David J
Weber, Sandra
Li, Nan-Sheng
Sauvage, Madline
Joiner, Carstyn F
Hancock, Govinda R
Sullivan, Emily A
Ndukwe, Estelle
Han, Ross
Cush, Sydney
Lainé, Muriel
Mader, Sylvie C
Greene, Geoffrey L
Fanning, Sean W
author_sort Hosfield, David J
collection PubMed
description Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα) cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene (Laso) derivatives that maintained the drug’s antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated Laso derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1. Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles.
format Online
Article
Text
id pubmed-9177151
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-91771512022-06-09 Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells Hosfield, David J Weber, Sandra Li, Nan-Sheng Sauvage, Madline Joiner, Carstyn F Hancock, Govinda R Sullivan, Emily A Ndukwe, Estelle Han, Ross Cush, Sydney Lainé, Muriel Mader, Sylvie C Greene, Geoffrey L Fanning, Sean W eLife Biochemistry and Chemical Biology Chemical manipulation of estrogen receptor alpha ligand binding domain structural mobility tunes receptor lifetime and influences breast cancer therapeutic activities. Selective estrogen receptor modulators (SERMs) extend estrogen receptor alpha (ERα) cellular lifetime/accumulation. They are antagonists in the breast but agonists in the uterine epithelium and/or in bone. Selective estrogen receptor degraders/downregulators (SERDs) reduce ERα cellular lifetime/accumulation and are pure antagonists. Activating somatic ESR1 mutations Y537S and D538G enable resistance to first-line endocrine therapies. SERDs have shown significant activities in ESR1 mutant setting while few SERMs have been studied. To understand whether chemical manipulation of ERα cellular lifetime and accumulation influences antagonistic activity, we studied a series of methylpyrollidine lasofoxifene (Laso) derivatives that maintained the drug’s antagonistic activities while uniquely tuning ERα cellular accumulation. These molecules were examined alongside a panel of antiestrogens in live cell assays of ERα cellular accumulation, lifetime, SUMOylation, and transcriptional antagonism. High-resolution x-ray crystal structures of WT and Y537S ERα ligand binding domain in complex with the methylated Laso derivatives or representative SERMs and SERDs show that molecules that favor a highly buried helix 12 antagonist conformation achieve the greatest transcriptional suppression activities in breast cancer cells harboring WT/Y537S ESR1. Together these results show that chemical reduction of ERα cellular lifetime is not necessarily the most crucial parameter for transcriptional antagonism in ESR1 mutated breast cancer cells. Importantly, our studies show how small chemical differences within a scaffold series can provide compounds with similar antagonistic activities, but with greatly different effects of the cellular lifetime of the ERα, which is crucial for achieving desired SERM or SERD profiles. eLife Sciences Publications, Ltd 2022-05-16 /pmc/articles/PMC9177151/ /pubmed/35575456 http://dx.doi.org/10.7554/eLife.72512 Text en © 2022, Hosfield et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Biochemistry and Chemical Biology
Hosfield, David J
Weber, Sandra
Li, Nan-Sheng
Sauvage, Madline
Joiner, Carstyn F
Hancock, Govinda R
Sullivan, Emily A
Ndukwe, Estelle
Han, Ross
Cush, Sydney
Lainé, Muriel
Mader, Sylvie C
Greene, Geoffrey L
Fanning, Sean W
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
title Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
title_full Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
title_fullStr Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
title_full_unstemmed Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
title_short Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
title_sort stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in esr1 mutant breast cancer cells
topic Biochemistry and Chemical Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177151/
https://www.ncbi.nlm.nih.gov/pubmed/35575456
http://dx.doi.org/10.7554/eLife.72512
work_keys_str_mv AT hosfielddavidj stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT webersandra stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT linansheng stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT sauvagemadline stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT joinercarstynf stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT hancockgovindar stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT sullivanemilya stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT ndukweestelle stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT hanross stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT cushsydney stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT lainemuriel stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT madersylviec stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT greenegeoffreyl stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells
AT fanningseanw stereospecificlasofoxifenederivativesrevealtheinterplaybetweenestrogenreceptoralphastabilityandantagonisticactivityinesr1mutantbreastcancercells